Licenses antibody discovery technology to pharmaceutical companies.
Jun 2026Revenue $38.5M/yrExpenses $86.8M/yr
No trendCash runway ≈ 2.9 years from Jun 2026
Figures by year
When will OmniAb be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $38.5M and expenses $86.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $18.7M | $87.6M | −$69.0M |
| Dec 2024 | $26.4M | $101M | −$74.5M |
| Dec 2023 | $34.2M | $104M | −$69.4M |
| Dec 2022 | $59.1M | $85.7M | −$26.6M |
| Dec 2021 | $34.7M | $70.4M | −$35.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.